Giorgio Scagliotti, President of IASLC said
: “Effective screening is key to finding and diagnosing lung cancer and other thoracic malignancies early, which can translate to more options and longer survival. Yet screening is underutilized around the world for several reasons. The application of quantitative imaging approaches like ELIC could improve the accuracy and the efficiency of lung cancer screening. Our platform is poised to become an important global resource for lung cancer researchers and care teams looking to expand their knowledge. The Lung Ambition Alliance is providing the focus, expertise, and resources needed to dramatically accelerate the expansion of our data catalogue.” 2. The Major Pathologic Response Project is a collection of clinical trial data and research that can be used to validate surrogate endpoints and identify predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of the next generation of targeted treatments and drive the shift to earlier intervention when there is greater potential for a cure.
5 The Alliance is assisting in the pooling of data from cooperative groups and across pharmaceutical industry trials, which can be used with health authorities around the world when discussing pivotal trial data.
AmirAli Talasaz, President and Chief Operating Officer, Guardant Health said
: “Precision medicine is improving prognosis for some lung cancer patients and delivering better clinical outcomes. We believe precision medicine approaches can be even more effective when utilized earlier in the course of the disease, or immediately upon detection of relapse. The Major Pathologic Response Project will help accelerate development of potentially curative treatment options, with the identification of surrogate endpoints that can be used to quicken clinical trials and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor prognosis, allow routine assessment of therapeutic response, and promote ongoing monitoring of cancer remission.” 3. Initiatives in Lung Cancer Care (ILC2) is an open call anticipated to launch in late 2019, inviting local patient organizations around the world to develop and submit pilot projects that can potentially transform patient care and improve survival at the local level. It aims to help the local lung cancer community benefit from multidisciplinary best practices, educate patients about their options and provide quality-of-life support to patients throughout and following treatment. A Lung Ambition Alliance committee will evaluate and select submissions that have met the selection criteria for funding.
Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, AstraZeneca, said:
“Lung cancer is a highly personal disease, and care approaches can vary widely around the world. In order to reach our survival goal, we must encourage initiatives that address barriers at the country level and increase screening and early diagnosis, aid the development of innovative medicine and improve quality care. By joining together with partners who have broad global networks and distinct but complementary areas of focus in lung cancer, we are better positioned to address issues those patients face.”The Alliance will sponsor an international survey, led by Ipsos MORI, to identify local barriers that need priority focus. Results, expected in the fall of 2019, will be used to further refine and shape the priorities of the Lung Ambition Alliance. Information about the survey, and how the community can share their perspectives, can be found at LungAmbitionAlliance.org.
About the Lung Ambition Alliance
The Lung Ambition Alliance is a flagship partnership of diverse organizations united in the quest to eliminate lung cancer as a cause of death. The Alliance aims to accelerate progress and bring meaningful change for lung cancer patients by amplifying the expertise of each partner and prioritizing meaningful projects with potential to further its goal. The founding partners – the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca – will explore and overcome barriers to screening and early diagnosis, the development of innovative medicine and quality care, and pursue an ambitious vision for the future in lung cancer that starts with doubling five-year survival by 2025.
For more information, visit www.lungambitionalliance.org.
About the Founding Partners
· The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies, with a global network of more than 6,500 lung cancer specialists across all disciplines in over 100 countries.
· The Global Lung Cancer Coalition is the international voice of lung cancer patients and committed to patient advocacy.
· Guardant Health is an innovative diagnostics company with a vision to enable earlier detection through access to molecular information in the blood.
· AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines.
CONTACTS:
Jennifer Corrigan
BursonRx
Jennifer.Corrigan@bursonrx.com+1-347-366-1444
Emma Barrow
GCI Health
Emma.Barrow@gcihealth.com +44-207-300-6114
Accelerating Advances for People with Lung Cancer.References
______________________
